Condition: NSCLC Stage IV · PD-L1 Gene Mutation · Atezolizumab · Sponsor: Antalya Training and Research Hospital
This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.
This description comes directly from the study's public registry record.
Derya Kıvrak Salim · +90 533 648 82 17 · derya.kivraksalim@sbu.edu.tr
Always discuss trial participation with your own doctor first.
| Adana City Hospital | Adana, Turkey (Türkiye) | Recruiting |
| Afyonkarahisar Health Sciences University Hospital | Afyonkarahisar, Turkey (Türkiye) | Recruiting |
| Ankara Oncology Training and Research Hospital | Ankara, Turkey (Türkiye) | Not Yet Recruiting |
| Memorial Ankara Hospital | Ankara, Turkey (Türkiye) | Not Yet Recruiting |
| Ankara Bilkent City Hospital | Ankara, Turkey (Türkiye) | Not Yet Recruiting |
| Ankara Atatürk Sanatoryum Training and Research Hospital | Ankara, Turkey (Türkiye) | Recruiting |
| Antalya Training and Research Hospital | Antalya, Turkey (Türkiye) | Recruiting |
| Antalya City Hospital | Antalya, Turkey (Türkiye) | Recruiting |
| Adnan Menderes University Faculty of Medicine Hospital | Aydin, Turkey (Türkiye) | Recruiting |
| Dicle University Hospital | Diyarbakır, Turkey (Türkiye) | Not Yet Recruiting |
| Trakya University Faculty of Medicine Hospital | Edirne, Turkey (Türkiye) | Recruiting |
| Gaziantep City Hospital | Gaziantep, Turkey (Türkiye) | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07279402